Key Highlights

● Curis priced a $5.6 million raise carrying an explicit going-concern warning, underscoring the company's thin financial cushion.

● The raise funds operations toward a December readout of leukemia data for lead candidate emavusertib.

● Curis has packed a lot into 2026: a January private placement, a 1-for-20 Reverse Stock Split in July, and an encouraging brain-lymphoma data update.

● The Lexington, Massachusetts oncology developer's Investment case now hinges heavily on the upcoming December leukemia readout.

Curis, Inc. (NASDAQ: CRIS), the Lexington, Massachusetts oncology developer behind emavusertib, has packed a lot into 2026: a January private placement, a 1-for-20 reverse stock split in July, an encouraging brain-lymphoma data update, and now a small, tightly priced Equity raise.

On 13 August 2026 Curis priced a $5.6 million public offering of shares and warrants at $1.50 per share, closing expected on or about 14 August. The prospectus is blunt: existing cash is not expected to fund operations beyond 12 months, and the raise will not remove substantial doubt about the company's ability to continue as a going concern.

That is the tension. Emavusertib, an oral inhibitor of IRAK4 - a signalling protein certain blood cancers rely on to keep growing - is producing responses in two hard-to-treat settings. But Curis entered August with a Market Value near $3.4 million and about 2.1 million shares outstanding after the split.

What Happened

Curis filed a Form S-1 for a best-efforts public offering on 10 August 2026. The SEC declared it effective on 12 August, and the final prospectus was filed on 13 August, the day pricing was announced.

The structure is typical for micro-cap biotech. Curis sold 335,001 common shares at $1.50 alongside 3,398,333 pre-funded warrants at $1.49, each unit carrying a five-year Warrant exercisable at $1.75. Pre-funded warrants are shares sold in advance at a nominal $0.01 exercise price, letting large holders stay under ownership caps.

After a 6.5% Placement agent fee of $364,000 and about $0.4 million of expenses, net proceeds are expected near $4.8 million, for Research and Development and working capital. A.G.P./Alliance Global Partners led the deal.

Why It Matters

The size of the raise is the story. In May, Curis told investors its $15.0 million of cash at 31 March 2026, plus up to $20.2 million anticipated from Series B warrants issued in the January private placement, should fund operations into the second half of 2027.

Those warrants carried a clinical trigger: they lapse 30 days after Curis announces a fifth patient dosed in its Phase 2 chronic lymphocytic leukemia study. That announcement came on 30 July. Their $0.75 exercise price, set before the split, equates to $15.00 afterwards - far above a stock that closed at $1.67 on 12 August.

Curis has not explained the gap between the $20.2 million once anticipated and the $5.6 million raised. The filings establish only that it went to the public market for a modest sum days after the trigger.

The Numbers

The most recent reported quarter is the first quarter of 2026; second-quarter results had not been published as of pricing. Curis recorded no Revenue in Q1, having sold its Erivedge Royalty stream in late 2025, against $2.4 million a year earlier.

Research and development spending fell to $6.4 million from $8.5 million, while general and administrative costs rose to $5.1 million from $4.0 million. A $12.7 million net other expense drove the net loss to $24.2 million, or $1.25 per share, versus $10.6 million a year earlier. Cash was $15.0 million at 31 March 2026.

Clinically, the 22 July update from the TakeAim Lymphoma study in relapsed or refractory primary CNS lymphoma showed a 100% objective response rate in patients never treated with a BTK inhibitor - five of five evaluable - and 33%, or 10 of 30 evaluable, among those already treated. At the May 2025 cutoff those figures were 86% (six of seven) and 26% (10 of 39).

Curis had 2,090,077 shares outstanding on 7 August. The deal adds 335,001 shares now, up to 3,398,333 on pre-funded warrant exercise and 3,733,334 more from the warrants.

What It Means for the Company

The cash keeps two lead programmes running rather than expanding them. Curis says its monotherapy and combination studies in acute myeloid leukemia are substantially complete and that further AML work depends on additional funding - an explicit narrowing onto primary CNS lymphoma and CLL.

That focus has regulatory backing. Curis says the FDA and EMA indicated in 2025 that the lymphoma study could support an Accelerated Approval application in relapsed or refractory primary CNS lymphoma, a setting with few options.

The CLL study, CA-4948-203, is an open-label Phase 2 pairing emavusertib with the BTK inhibitor zanubrutinib in patients in partial response who still have measurable residual disease. Eleven sites are open, ten patients had consented and five were dosed as of 30 July. HC Wainwright analyst Sara Nik reiterated a Buy rating on 24 July and lifted her price target to $43 from $17.

Risks Investors Should Watch

Financing risk sits at the top. The prospectus states the proceeds will not be sufficient to alleviate substantial doubt about the going concern, which points to further raises.

Listing risk is close behind. Curis regained compliance with Nasdaq's market value standard, Rule 5550(b)(2), on 3 February 2026, but sits under a one-year discretionary panel monitor to February 2027, in which a new deficiency goes straight to delisting with no cure period. Nasdaq issued a delist determination on 27 April over the $1.00 bid price rule; Curis requested a hearing on 4 May, staying suspension, and executed the split on 2 July.

The clinical numbers are early and small. Response rates from five or thirty evaluable patients in a single-arm study can move sharply as enrolment grows, and response is not the same as durable benefit. Dilution is live: the new warrants plus remaining January tranches are a heavy overhang on a 2.1 million share base.

What Comes Next

The nearest items are administrative: the offering was due to close on or about 14 August, and second-quarter statements are due around mid-August, giving the first look at cash at 30 June.

The Series B warrant window lapses roughly 30 days after the 30 July dosing announcement, so late August should clarify whether any of that capital arrives.

The main catalyst is initial TakeAim CLL data, guided for December 2026 and now covering five to ten patients after Curis raised guidance from five. Updated primary CNS lymphoma data is guided for the first half of 2027.

The Road to December's Leukemia Data

Curis draws attention because two things are true at once. Emavusertib is generating responses in pretreated patients, regulators have signalled an accelerated approval route, and a readout lands in December.

At the same time it runs on a few million dollars of fresh capital, carries a going-concern warning, sits under a Nasdaq panel monitor, and has just repriced equity at $1.50.